Coeptis Therapeutics (NASDAQ:ZSQR) Releases Earnings Results

Coeptis Therapeutics (NASDAQ:ZSQR) issued its earnings results on Thursday. The company reported ($0.28) EPS for the quarter, Zacks reports. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.

Coeptis Therapeutics Price Performance

ZSQR stock traded up $0.27 during mid-day trading on Thursday, reaching $4.16. 398,778 shares of the company’s stock were exchanged, compared to its average volume of 260,849. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.25 and a quick ratio of 3.25. Coeptis Therapeutics has a 12-month low of $3.77 and a 12-month high of $21.41. The stock’s 50 day moving average is $8.56 and its 200 day moving average is $10.86. The company has a market cap of $213.95 million, a price-to-earnings ratio of -1.65 and a beta of -0.20.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ZSQR. Steward Partners Investment Advisory LLC lifted its position in shares of Coeptis Therapeutics by 100.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after buying an additional 2,500 shares in the last quarter. Marshall Wace LLP acquired a new stake in Coeptis Therapeutics in the 4th quarter valued at $259,000. State Street Corp increased its holdings in Coeptis Therapeutics by 35.0% in the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after acquiring an additional 6,962 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Coeptis Therapeutics by 12.6% in the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after acquiring an additional 4,721 shares in the last quarter. 13.88% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Wall Street Zen downgraded Coeptis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.